Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
在接受英夫利昔单抗和维多珠单抗治疗的炎症性肠病患者接种三剂新冠疫苗后，针对SARS-CoV-2野生型和omicron BA.1及BA.4/5变异株的中和抗体效力（CLARITY IBD）：一项前瞻性多中心队列研究的分析
期刊:Lancet Gastroenterology & Hepatology
影响因子:38.6
doi:10.1016/S2468-1253(22)00389-2
Liu, Zhigang; Le, Kaixing; Zhou, Xin; Alexander, James L; Lin, Simeng; Bewshea, Claire; Chanchlani, Neil; Nice, Rachel; McDonald, Timothy J; Lamb, Christopher A; Sebastian, Shaji; Kok, Klaartje; Lees, Charlie W; Hart, Ailsa L; Pollok, Richard C; Boyton, Rosemary J; Altmann, Daniel M; Pollock, Katrina M; Goodhand, James R; Kennedy, Nicholas A; Ahmad, Tariq; Powell, Nick
